Sabitlenmiş Tweet
Ruella Lab is proud to announce that @MarcoRuella has won @BloodCancerUtd Greater Philadelphia Visionary of the Year!
Thanks to all supporters to our campaign, YOU made a HUGE contribution to fight cancer!
@PennMedicine
English
Ruella Lab
51 posts
Ruella Lab
@RuellaLab
We focus on mechanisms of relapse after CAR-T therapy. Our goal is to design innovative combined IMT for relapsing/refractory Leukemia & Lymphoma. @MarcoRuella
Philadelphia, PA Katılım Aralık 2019
50 Takip Edilen259 Takipçiler
We are excited to share our work demonstrating 10-year remissions after one infusion of Tisa-cel in B-NHL patients!
nejm.org/doi/abs/10.105
We thank all the patients & families, as well as the clinical & research teams that made this work possible.
@MarcoRuella @PennMedicine
English
In last week's episode of Blood Podcast, editor Dr. Laura Michaelis interviews @MarcoRuella on recent work on harnessing the CD2 axis to enhance CAR T-cell therapies.
@PennMedicine
share.transistor.fm/s/ce15a794
English
For those of you in Philly, come support our bake sale in the Perelman Center upstairs lobby! 🍪 🍰
All proceeds will support Blood Cancer United! 🩸
English
Great job to our PhD candidate Audrey for the wonderful presentation at @ISCTglobal! Read more about this work in our @ScienceTM publication.
Also great presentation by Dr. Bruce Levine (@BLLPHD), thank you for featuring our work from @CellCellPress
@MarcoRuella @PennMedicine
English
Amazing presentation this morning at CCI, @PennCancer @PennMedCSO!
• @MarcoRuella presented correlative data from the Phase 1 Senza5-CAR5 study;
• @LemoineJean6 introduced a novel CAR T-cell design targeting IGHV1-69 on B-cell receptors.
Proud to help develop next-gen CAR T!
English
Ruella Lab retweetledi
Harnessing the CD2 axis to broaden & enhance the efficacy of CAR T-cell therapies ft. @AlbertoCarturan, @Mat_Angelos & @MarcoRuella (@PennCancer) @RuellaLab @BloodPortfolio ashpublications.org/blood/article-…
English
Congrats to @BernhardDumoul1, @KSusztak, and the rest of the Susztak lab for the amazing work in @Nature! We are happy to be involved, and excited to see what comes next!
@PennMedicine @MarcoRuella
Katalin Susztak@KSusztak
🗞️📸🌟🤩Beautiful work led by @BernhardDumoul1 with the team builds a single cell spatial atlas of human DKD using Xenium + CosMx + snRNA-seq. @Nature This is not incremental. This is a new layer of pathology. Diabetic kidney disease (DKD) is still treated as one disease. That is the problem. Patients look similar clinically but behave very differently. We asked: is there a biologically distinct subgroup we are missing? rdcu.be/ff6ZZ
English
Thank you @PennMedicine for the support! And of course thank you @CellCellPress @BloodPortfolio @ScienceTM and @NEJM (out soon) for the opportunity to publish with you all!
English
A celebration dinner for all of our recent accomplishments!
⭐️ 4 publications out so far in 2026
⭐️ 2 covers (@BloodPortfolio Vol 147 Issue 16, and @ScienceTM Vol 18 Issue 835)
And so much more to come!
@MarcoRuella
English
Ruella Lab retweetledi
CD2 is a viable target for CAR T-cell immunotherapy for T-cell malignancies, but CD2 deletion in CAR T cells can lead to dysfunction. Read in Blood: ow.ly/j41050YKAiI
English
‼️Ruella Lab at the Heme Malignancies Research in Progress session!
Presenters:
🩸@Shan_Liu_ discusses how host factors such as diet can modulate responses to CAR T-cell therapy
🩸@paruzzol presents on the decade-long persistence of CAR T-cells
@MarcoRuella @PennMedicine
English
Ruella Lab retweetledi
New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: ashpublications.org/blood/issue/14…
English
📣Out today in @BloodPortfolio: harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.
🔗 authors.elsevier.com/a/1my0Z1UYwuoRi
Congrats to @AlbertoCarturan & @Mat_Angelos!
@MarcoRuella @PennMedicine @PennCancer @PennMedCSO
English
Ruella Lab is proud to support @MarcoRuella as a 2026 Visionaries of the Year candidate for Blood Cancer United!
Advancing therapies for blood cancers is at the heart of our work.
Help us reach $50K by June 12—every penny counts.
Donate & share 👇
🔗 pages.lls.org/voy/epa/philly…
English
@ASH_hematology Thank you for highlighting our lab! This snapshot is just one small piece of the broader effort that keeps hematology strong and advancing—especially in challenging times.
English
Ruella Lab retweetledi
When political threats put scientific research at risk, your support of the ASH Foundation helped keep hematology vibrant and rewarding. Thank you for driving positive change in hematology. View the 2025 ASH Annual Report: ow.ly/2l5750YzTQT
#Fight4Hematology
English
Ruella Lab retweetledi
New research out @CellCellPress in finds that β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer ft. @Shan_Liu_ & @RuellaLab (@PennCancer) sciencedirect.com/science/articl…
English
Ruella Lab retweetledi
CAR T cell therapy has shown strong results against certain cancers, but metabolic exhaustion limits its effectiveness over time.
In @CellCellPress, the @MaayanLevyPhD & @ChristophThaiss labs report that a common supplement can fuel CAR T cells to fight cancer more effectively.
English
Ruella Lab retweetledi
Excited to share our new paper in @CellCellPress with @MarcoRuella, led by @Shan_Liu_
and @PuneethGuru_. CAR T cell therapy loses effectiveness over time due to metabolic exhaustion, but we found a surprisingly simple approach to address it. 👇
cell.com/cell/abstract/…
English